Estrella Immunopharma Net Income From Continuing Ops Over Time
| ESLA Stock | 1.38 0.07 4.83% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Estrella Immunopharma Performance and Estrella Immunopharma Correlation. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Estrella Immunopharma. Projected growth potential of Estrella fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Estrella Immunopharma assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of Estrella Immunopharma is measured differently than its book value, which is the value of Estrella that is recorded on the company's balance sheet. Investors also form their own opinion of Estrella Immunopharma's value that differs from its market value or its book value, called intrinsic value, which is Estrella Immunopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Estrella Immunopharma's market value can be influenced by many factors that don't directly affect Estrella Immunopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Estrella Immunopharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Estrella Immunopharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Estrella Immunopharma's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Net Income From Continuing Ops Analysis
Compare Estrella Immunopharma and related stocks such as eXoZymes, Greenwich Lifesciences, and Atossa Genetics Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EXOZ | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.4 M) | (2 M) | (5.9 M) | (5.3 M) | (5 M) |
| GLSI | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (3.4 M) | (1.9 M) | (4.6 M) | (7.8 M) | (8.9 M) | (15.8 M) | (14.2 M) | (13.5 M) |
| ATOS | (5.1 M) | (5.1 M) | (5.1 M) | (10.8 M) | (14.7 M) | (12.8 M) | (6.4 M) | (8.1 M) | (11.4 M) | (17.2 M) | (17.8 M) | (20.6 M) | (27 M) | (29.8 M) | (25.5 M) | (23 M) | (24.1 M) |
| SRZN | (32.7 M) | (32.7 M) | (32.7 M) | (32.7 M) | (32.7 M) | (32.7 M) | (32.7 M) | (32.7 M) | (32.7 M) | (32.7 M) | (32.7 M) | (54.6 M) | (36 M) | (34.9 M) | (63.6 M) | (57.2 M) | (60.1 M) |
| ANEB | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (11.7 M) | (11.6 M) | (8.2 M) | (8.5 M) | (9.8 M) | (10.2 M) |
| TVGN | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | 4.4 M | (67.3 K) | (13.7 M) | (15.8 M) | (15 M) |
| ONCY | 0.0 | 0.0 | 0.0 | 0.0 | (16 M) | (5.2 M) | (15.1 M) | (15.6 M) | (17 M) | (33.1 M) | (22.5 M) | (26.3 M) | (24.8 M) | (32.4 M) | (31.7 M) | (28.5 M) | (27.1 M) |
| TIL | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (37.7 M) | (156.8 M) | (223.2 M) | (197 M) | (74.1 M) | (66.7 M) | (70.1 M) |
| TLSA | (19.6 M) | (19.6 M) | (19.6 M) | (19.6 M) | (19.6 M) | (417.5 M) | (7.2 M) | (6.8 M) | (6.3 M) | (7.3 M) | (26.1 M) | (23.4 M) | (15.4 M) | (17.7 M) | (11.9 M) | (13.6 M) | (14.3 M) |
| IMMX | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (1.1 M) | (24.4 M) | (8.2 M) | (14.2 M) | (21.7 M) | (19.5 M) | (18.6 M) |
Estrella Immunopharma and related stocks such as eXoZymes, Greenwich Lifesciences, and Atossa Genetics Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| Estrella Immunopharma | ESLA |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 5858 Horton Street, |
| Exchange | NASDAQ Exchange |
null 1.38
Check out Estrella Immunopharma Performance and Estrella Immunopharma Correlation. For information on how to trade Estrella Stock refer to our How to Trade Estrella Stock guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Estrella Immunopharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.